Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions Current and Future Trends /

This resource guides prescribers, pharmacists, and regulators with an update on the recent expansion of basic and clinical knowledge that forms a framework for understanding cutaneous reactions. This understanding will lead, in turn, to better outcomes and decisions in treatment and management, both...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Συγγραφή απο Οργανισμό/Αρχή: SpringerLink (Online service)
Άλλοι συγγραφείς: Shear, Neil H. (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt), Dodiuk-Gad, Roni P. (Επιμελητής έκδοσης, http://id.loc.gov/vocabulary/relators/edt)
Μορφή: Ηλεκτρονική πηγή Ηλ. βιβλίο
Γλώσσα:English
Έκδοση: Singapore : Springer Singapore : Imprint: Adis, 2019.
Έκδοση:1st ed. 2019.
Θέματα:
Διαθέσιμο Online:Full Text via HEAL-Link
LEADER 04390nam a2200469 4500
001 978-981-13-1489-6
003 DE-He213
005 20191029021947.0
007 cr nn 008mamaa
008 181019s2019 si | s |||| 0|eng d
020 |a 9789811314896  |9 978-981-13-1489-6 
024 7 |a 10.1007/978-981-13-1489-6  |2 doi 
040 |d GrThAP 
050 4 |a RS1-441 
072 7 |a MMG  |2 bicssc 
072 7 |a MED071000  |2 bisacsh 
072 7 |a MKG  |2 thema 
082 0 4 |a 353.998  |2 23 
245 1 0 |a Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions  |h [electronic resource] :  |b Current and Future Trends /  |c edited by Neil H. Shear, Roni P. Dodiuk-Gad. 
250 |a 1st ed. 2019. 
264 1 |a Singapore :  |b Springer Singapore :  |b Imprint: Adis,  |c 2019. 
300 |a XII, 314 p. 95 illus., 91 illus. in color.  |b online resource. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
347 |a text file  |b PDF  |2 rda 
505 0 |a Section I. Introduction -- 1. Introduction: Classification, Terminology, Epidemiology and Etiology of Cutaneous Adverse Drug Reactions -- Section II. Pathomechanisms of Cutaneous Adverse Drug Reactions -- 2. Immunology of Cutaneous Adverse Drug Reactions -- 3. Pharmacogenomics and Cutaneous Adverse Drug Reactions -- 4 Viral Reactivation in Cutaneous Adverse Drug Reactions -- 5. Using Technology to Learn About Immunology of Cutaneous Adverse Drug Reactions -- Section III. Clinical Perspectives of Cutaneous Adverse Drug Reactions -- 6. Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (Epithelial Necrolysis) -- 7. Drug Reaction with Eosinophilia and Systemic Symptoms -- 8. Acute Generalized Exanthematous Pustulosis -- 9. Urticarial Reactions to Drugs -- 10. Dermatological Adverse Events from Cancer Treatments -- 11. Cutaneous Adverse Drug Reactions in Pediatric Population -- 12. Cutaneous Drug Reactions in the Elderly -- 13. Cutaneous Adverse Drug Reactions in Human Immunodeficiency Virus Patients -- 14. Cutaneous Adverse Drug Reactions from Anti-Tuberculosis Treatment -- Section IV. Approach to the Patient with a Cutaneous Adverse Drug Reaction -- 15. Practical Approach to Diagnosis and Management of Cutaneous Adverse Drug Reactions -- 16. Histopathology of Severe Drug Eruptions -- 17. Evaluation of Drug Safety Literature: A Guide for the Practicing Dermatologist -- 18. In vitro and in vivo tests in Cutaneous Adverse Drug Reactions -- 19. Pharmacovigilance of Cutaneous Adverse Drug Reactions -- Section V. Epilogue -- 20. Future Directions and Unmet Research Needs in Cutaneous Adverse Drug Reactions -- 21. Atlas of Cutaneous Adverse Drug Reactions. 
520 |a This resource guides prescribers, pharmacists, and regulators with an update on the recent expansion of basic and clinical knowledge that forms a framework for understanding cutaneous reactions. This understanding will lead, in turn, to better outcomes and decisions in treatment and management, both in the clinic and in the life cycle of drug development. The skin is a common target for adverse drug events and even mild rashes can be part of life-threatening syndromes. Patients and practitioners often face important decisions about therapy after a drug eruption, including treatment, cross-reactivity with future pharmaceuticals, genetic considerations and dealing with long-term sequelae after a reaction. An international team of experts and leaders in the field share their story and insights into the scientific details and relevant clinical context. 
650 0 |a Pharmacy. 
650 0 |a Pharmacology. 
650 1 4 |a Drug Safety and Pharmacovigilance.  |0 http://scigraph.springernature.com/things/product-market-codes/H69010 
650 2 4 |a Pharmacology/Toxicology.  |0 http://scigraph.springernature.com/things/product-market-codes/B21007 
700 1 |a Shear, Neil H.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
700 1 |a Dodiuk-Gad, Roni P.  |e editor.  |4 edt  |4 http://id.loc.gov/vocabulary/relators/edt 
710 2 |a SpringerLink (Online service) 
773 0 |t Springer eBooks 
776 0 8 |i Printed edition:  |z 9789811314889 
776 0 8 |i Printed edition:  |z 9789811314902 
776 0 8 |i Printed edition:  |z 9789811346415 
856 4 0 |u https://doi.org/10.1007/978-981-13-1489-6  |z Full Text via HEAL-Link 
912 |a ZDB-2-SME 
950 |a Medicine (Springer-11650)